TecMed to acquire diabetes care business of Ypsomed for $520m.

TecMed, a provider of intellectual property solutions to blood glucose measurement problems, agreed to acquire diabetes care business of Ypsomed, a provider of a complete range of technologies and services for reliable and user-friendly injection systems for self-medication, for $520m. "We are focusing on capturing substantial opportunities in the subcutaneous self-injection market and expanding our global production capacities. Our fundamental growth drivers – the increasing popularity of selfcare, as well as the rise of biologics and biosimilars – continue to offer enormous potential. Thanks to our automated and scalable processes, we are well positioned to significantly participate in this growth," Simon Michel, Ypsomed CEO.